CIDARA THERAPEUTICS, INC. Selling, General and Administrative Expense
CIDARA THERAPEUTICS, INC. reported Selling, General and Administrative Expense of $8.10 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-11-06
- CIDARA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $8.10M, a 63.12% increase year-over-year.
- CIDARA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-06-30 was $6.50M, a 37.00% increase year-over-year.
- CIDARA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-03-31 was $6.18M, a 71.83% increase year-over-year.
- CIDARA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2024-09-30 was $4.96M, a 50.50% increase year-over-year.
- CIDARA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2023 was $18.33M, a 10.77% decline from fiscal 2022.
- CIDARA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2022 was $20.55M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | $8.10M 10-Q · filed 2025-11-06 | $14.60M derived: sum of 2 quarters · filed 2025-11-06 | $20.78M 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $6.50M 10-Q · filed 2025-08-07 | $12.68M 10-Q · filed 2025-08-07 | |||||
| 2025-03-31 | $6.18M 10-Q · filed 2025-05-08 | ||||||
| 2024-09-30 | $4.96M 10-Q · filed 2025-11-06 | $9.71M derived: sum of 2 quarters · filed 2025-11-06 | $13.31M 10-Q · filed 2025-11-06 | $21.51M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $4.75M 10-Q · filed 2025-08-07 | $8.34M 10-Q · filed 2025-08-07 | $16.54M derived: sum of 3 quarters · filed 2025-08-07 | $19.84M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $3.60M 10-Q · filed 2025-05-08 | $6.00M 10-Q · filed 2024-05-15 | $11.80M derived: sum of 2 quarters · filed 2025-05-08 | $15.10M derived: sum of 3 quarters · filed 2025-05-08 | $18.28M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-22 | $11.50M derived: sum of 2 quarters · filed 2024-11-07 | $14.68M derived: sum of 3 quarters · filed 2024-11-07 | $18.33M 10-K · filed 2024-04-22 | |||
| 2023-09-30 | $3.30M 10-Q · filed 2024-11-07 | $4.43M 10-K · filed 2024-04-22 | $6.48M derived: sum of 2 quarters · filed 2024-11-07 | $10.13M 10-Q · filed 2024-11-07 | $12.93M 10-K · filed 2024-04-22 | $14.53M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $3.18M 10-Q · filed 2024-08-13 | $4.04M 10-K · filed 2024-04-22 | $6.83M 10-Q · filed 2024-08-13 | $8.50M 10-K · filed 2024-04-22 | $11.23M derived: sum of 3 quarters · filed 2024-08-13 | $17.50M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $4.46M 10-Q · filed 2024-05-15 | $8.05M derived: sum of 2 quarters · filed 2024-05-15 | $14.32M derived: sum of 3 quarters · filed 2024-05-15 | $19.66M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $3.60M derived: 10-K 12 month − 10-K 9 month · filed 2024-04-22 | $9.87M derived: sum of 2 quarters · filed 2024-04-22 | $15.20M derived: sum of 3 quarters · filed 2024-04-22 | $20.55M 10-K · filed 2024-04-22 | |||
| 2022-09-30 | $6.27M 10-K · filed 2024-04-22 | $11.61M derived: sum of 2 quarters · filed 2024-04-22 | $16.95M 10-K · filed 2024-04-22 | ||||
| 2022-06-30 | $5.34M 10-K · filed 2024-04-22 | $10.68M 10-K · filed 2024-04-22 | |||||
| 2022-03-31 | $5.34M 10-K · filed 2024-04-22 |